Indian pharmaceutical company Ajanta Pharma Limited has announced the launch of Eletriptan Hydrobromide tablets (20 mg and 40 mg) in the US market through its US subsidiary, the company said in a statement on Thursday.
Eletriptan is a second generation triptan drug which helps treat headache, pain, and other migraine symptoms.
The drug is bioequivalent generic version of Relpax tablets, a branded drug marketed and manufactured by Pfizer in the US and Canada. It is sold in other countries under the brand name Relert.
The drug is part of Ajanta’s growing portfolio of products that are being developed specifically for the US market.
According to Mumbai-headquartered pharma company, it has submitted 35 Abbreviated New Drug Applications (ANDAs) with US Food and Drug Administration (USFDA) and has managed to receive 19 final ANDA approvals from the drug regulator. There are also two tentative approvals, while 14 ANDAs are under review with USFDA.
So far the company, which is engaged in developing, manufacturing and marketing of quality drugs across more than 30 countries, has launched 14 products in the US market.